Abstract
Sarilumab (Kevzara) represents a new effective option of inhibiting IL-6 signaling treatment in the treatment of various patient groups with rheumatoid arthritis. Not only in combination with methotrexate but also in monotherapy, patients with active moderate to severe illness can significantly improve not only clinical, functional and radiographic parameters, but also improve the quality of life, based on data from clinical trials.
Last but not least, sarilumab belongs to well tolerated drugs with a good profile.